Index RUT
P/E -
EPS (ttm) -1.08
Insider Own 4.61%
Shs Outstand 147.77M
Perf Week -2.61%
Market Cap 1.11B
Forward P/E -
EPS next Y -0.70
Insider Trans -16.46%
Shs Float 141.74M
Perf Month -3.86%
Income -159.49M
PEG -
EPS next Q -0.29
Inst Own 92.58%
Short Float 6.69%
Perf Quarter 20.68%
Sales 178.96M
P/S 6.20
EPS this Y 14.71%
Inst Trans 0.38%
Short Ratio 5.11
Perf Half Y 45.33%
Book/sh 1.37
P/B 5.45
EPS next Y 24.31%
ROA -26.57%
Short Interest 9.49M
Perf Year 178.73%
Cash/sh 1.50
P/C 4.99
EPS next 5Y 28.67%
ROE -62.41%
52W Range 2.28 - 9.01
Perf YTD 24.60%
Dividend Est. -
P/FCF -
EPS past 5Y -1.51%
ROI -38.50%
52W High -17.09%
Beta 1.73
Dividend TTM -
Quick Ratio 2.81
Sales past 5Y 17.92%
Gross Margin 53.95%
52W Low 227.63%
ATR (14) 0.66
Dividend Ex-Date -
Current Ratio 2.89
EPS Y/Y TTM 30.45%
Oper. Margin -86.27%
RSI (14) 45.73
Volatility 9.77% 9.20%
Employees 619
Debt/Eq 1.10
Sales Y/Y TTM 5.10%
Profit Margin -89.12%
Recom 1.25
Target Price 9.71
Option/Short Yes / Yes
LT Debt/Eq 1.04
EPS Q/Q 52.38%
Payout -
Rel Volume 1.46
Prev Close 7.41
Sales Surprise 3.06%
EPS Surprise 10.26%
Sales Q/Q 3.66%
Earnings Feb 11 AMC
Avg Volume 1.86M
Price 7.47
SMA20 -2.87%
SMA50 -5.14%
SMA200 29.92%
Trades
Volume 2,712,584
Change 0.81%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-21-25 Upgrade
Goldman
Neutral → Buy
$9
Jul-05-23 Resumed
JP Morgan
Overweight
$15
Jan-05-23 Initiated
Scotiabank
Sector Outperform
$15
Dec-21-22 Upgrade
Piper Sandler
Neutral → Overweight
$7.50 → $14
Aug-25-22 Initiated
Credit Suisse
Underperform
$8
Jun-03-22 Initiated
Piper Sandler
Neutral
$7.50
Feb-16-22 Reiterated
JP Morgan
Overweight
$75 → $50
Feb-16-22 Reiterated
Goldman
Neutral
$54 → $21
Feb-16-22 Reiterated
BTIG Research
Buy
$35 → $30
Feb-16-22 Reiterated
BofA Securities
Buy
$40 → $32
Oct-15-21 Resumed
Cowen
Outperform
Mar-03-21 Downgrade
Goldman
Buy → Neutral
$74 → $63
Oct-08-20 Resumed
BTIG Research
Buy
$60
Sep-09-20 Initiated
Morgan Stanley
Equal-Weight
$42
Jun-03-20 Initiated
Goldman
Buy
$60
Jul-23-19 Initiated
BTIG Research
Buy
$46
Jul-22-19 Initiated
William Blair
Outperform
Jul-22-19 Initiated
Guggenheim
Buy
$47
Jul-22-19 Initiated
Goldman
Neutral
$32
Jul-22-19 Initiated
Cowen
Outperform
Show Previous Ratings
Mar-20-25 03:06PM
Mar-11-25 08:00AM
Feb-14-25 10:44AM
Feb-12-25 12:00PM
09:56AM
(Thomson Reuters StreetEvents)
09:40AM
Loading…
09:40AM
02:11AM
Feb-11-25 06:30PM
05:35PM
04:45PM
(Associated Press Finance)
04:05PM
Feb-10-25 07:19AM
Feb-05-25 04:05PM
Feb-04-25 10:28AM
Jan-23-25 05:06PM
06:21AM
Loading…
06:21AM
Jan-22-25 04:05PM
Jan-17-25 09:40AM
Jan-16-25 08:33AM
Jan-15-25 10:10AM
Jan-14-25 07:30AM
Jan-07-25 07:30AM
Jan-02-25 04:05PM
Dec-09-24 09:53AM
Dec-07-24 06:30PM
Dec-05-24 07:16AM
Dec-03-24 07:30AM
Nov-29-24 09:40AM
Nov-25-24 01:55PM
(Clinical Trials Arena) +18.98%
Nov-15-24 09:55AM
10:18AM
Loading…
Nov-08-24 10:18AM
(Thomson Reuters StreetEvents)
02:29AM
Nov-07-24 06:30PM
06:15PM
05:11PM
(Associated Press Finance)
04:05PM
07:30AM
Nov-06-24 07:28AM
Oct-09-24 04:05PM
Oct-04-24 04:35AM
(Life Insurance International) +9.09%
Aug-29-24 07:30AM
Aug-22-24 04:03PM
Aug-01-24 07:00PM
06:20PM
05:23PM
(Associated Press Finance)
04:05PM
Jul-21-24 06:00AM
Jul-15-24 12:00PM
Jul-11-24 04:05PM
May-31-24 07:30AM
May-29-24 04:05PM
May-25-24 08:30AM
May-24-24 09:58AM
May-23-24 06:00AM
May-16-24 02:30PM
May-08-24 06:43PM
12:19PM
03:54AM
May-07-24 07:30PM
05:47PM
05:40PM
04:37PM
(Associated Press Finance)
04:05PM
Apr-26-24 10:02AM
Apr-17-24 04:05PM
Apr-02-24 04:05PM
Mar-27-24 04:30PM
08:30AM
Mar-11-24 12:01AM
Feb-22-24 04:05PM
Feb-15-24 10:09AM
06:37AM
(Thomson Reuters StreetEvents)
Feb-14-24 05:16PM
04:43PM
(Associated Press Finance)
04:05PM
Feb-13-24 02:23AM
Feb-12-24 09:16AM
Jan-29-24 04:05PM
Dec-27-23 04:05PM
Dec-12-23 05:50AM
Dec-11-23 03:30PM
Dec-09-23 08:30AM
Dec-05-23 07:30AM
Nov-10-23 01:52PM
Nov-09-23 04:17PM
(Associated Press Finance)
04:05PM
Nov-07-23 07:30AM
Nov-02-23 04:05PM
Oct-26-23 10:02AM
Oct-17-23 07:57AM
Sep-27-23 05:14AM
Sep-13-23 07:30AM
Aug-30-23 04:30PM
Aug-28-23 11:53PM
Aug-24-23 10:29AM
Aug-02-23 05:35PM
04:30PM
(Associated Press Finance)
04:05PM
Jul-29-23 12:12AM
Jul-19-23 08:52AM
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROBINS HARLAN S Chief Scientific Officer Mar 24 '25 Option Exercise 6.32 1,698 10,731 1,281,222 Mar 26 06:48 PM ROBINS HARLAN S Chief Scientific Officer Mar 24 '25 Sale 9.00 1,698 15,282 1,279,524 Mar 26 06:48 PM Harlan Robins Officer Mar 24 '25 Proposed Sale 8.66 1,698 14,705 Mar 24 05:45 PM PISKEL KYLE Chief Financial Officer Mar 14 '25 Option Exercise 6.32 2,500 15,800 271,510 Mar 17 07:34 PM GRIFFIN MICHELLE RENEE Director Mar 13 '25 Sale 7.19 36,291 260,932 15,394 Mar 17 07:33 PM GRIFFIN MICHELLE RENEE Director Mar 13 '25 Proposed Sale 7.19 36,291 260,861 Mar 13 05:28 PM HERSHBERG ROBERT Director Mar 12 '25 Sale 7.59 53,000 402,270 69,690 Mar 12 07:48 PM NEUPERT PETER M Director Mar 10 '25 Option Exercise 4.07 50,000 203,500 234,690 Mar 12 07:47 PM NEUPERT PETER M Director Mar 10 '25 Sale 7.05 10,000 70,500 224,690 Mar 12 07:47 PM HERSHBERG ROBERT Director Mar 12 '25 Proposed Sale 7.59 53,000 402,270 Mar 12 05:30 PM NEUPERT PETER M Director Mar 10 '25 Proposed Sale 7.05 10,000 70,450 Mar 10 02:48 PM LO FRANCIS Chief People Officer Mar 05 '25 Sale 6.99 20,875 145,845 332,846 Mar 06 07:22 PM BOBULSKY SUSAN Chief Commercial Officer, MRD Mar 05 '25 Sale 6.98 26,023 181,641 347,238 Mar 06 07:22 PM BENZENO SHARON Chief Commercial Ofc Imm Med Mar 05 '25 Sale 6.98 44,665 311,792 392,723 Mar 06 07:21 PM PISKEL KYLE Chief Financial Officer Mar 05 '25 Sale 6.98 10,320 72,072 269,010 Mar 06 07:20 PM RUBINSTEIN JULIE President and COO Mar 05 '25 Sale 6.98 59,505 415,540 588,249 Mar 06 07:19 PM ROBINS HARLAN S Chief Scientific Officer Mar 05 '25 Sale 6.99 96,656 675,219 1,279,524 Mar 06 07:18 PM ROBINS CHAD M CEO and Chairman Mar 05 '25 Sale 6.98 117,351 819,471 2,814,350 Mar 06 07:17 PM ROBINS CHAD M CEO and Chairman Mar 06 '25 Sale 7.64 102,218 780,946 2,959,249 Mar 06 07:17 PM GRIFFIN MICHELLE RENEE Director Mar 06 '25 Sale 7.94 15,664 124,372 51,685 Mar 06 07:14 PM MICHELLE GRIFFIN Director Mar 06 '25 Proposed Sale 7.94 15,664 124,440 Mar 06 04:10 PM ROBINS CHAD M CEO and Chairman Feb 19 '25 Option Exercise 6.32 186,080 1,176,026 2,762,781 Feb 21 07:28 PM ROBINS CHAD M CEO and Chairman Feb 20 '25 Option Exercise 6.32 99,107 626,356 2,675,808 Feb 21 07:28 PM ROBINS CHAD M CEO and Chairman Feb 19 '25 Sale 8.46 186,080 1,574,237 2,576,701 Feb 21 07:28 PM ROBINS CHAD M CEO and Chairman Feb 20 '25 Sale 8.44 99,107 836,463 2,576,701 Feb 21 07:28 PM Chad Robins Officer Feb 20 '25 Proposed Sale 8.37 99,107 829,526 Feb 20 04:02 PM Chad Robins Officer Feb 19 '25 Proposed Sale 8.37 186,080 1,557,490 Feb 19 04:51 PM ROBINS CHAD M CEO and Chairman Feb 18 '25 Option Exercise 6.32 211,160 1,334,531 2,787,861 Feb 18 08:21 PM ROBINS CHAD M CEO and Chairman Feb 14 '25 Option Exercise 6.32 158,921 1,004,381 2,735,622 Feb 18 08:21 PM ROBINS CHAD M CEO and Chairman Feb 13 '25 Option Exercise 6.32 100,287 633,814 2,676,988 Feb 18 08:21 PM ROBINS CHAD M CEO and Chairman Feb 18 '25 Sale 8.50 211,160 1,794,860 2,576,701 Feb 18 08:21 PM ROBINS CHAD M CEO and Chairman Feb 14 '25 Sale 8.46 158,921 1,344,472 2,576,701 Feb 18 08:21 PM ROBINS CHAD M CEO and Chairman Feb 13 '25 Sale 8.44 100,287 846,422 2,576,701 Feb 18 08:21 PM Chad Robins Officer Feb 18 '25 Proposed Sale 8.27 211,160 1,746,293 Feb 18 05:35 PM Chad Robins Officer Feb 14 '25 Proposed Sale 8.33 158,921 1,323,812 Feb 14 04:11 PM Chad Robins Officer Feb 13 '25 Proposed Sale 8.52 100,287 854,445 Feb 13 05:11 PM PISKEL KYLE Chief Financial Officer Nov 18 '24 Sale 4.98 248 1,235 154,330 Nov 19 06:45 PM BOBULSKY SUSAN Chief Commercial Officer, MRD Oct 08 '24 Option Exercise 1.98 5,000 9,900 253,290 Oct 10 05:47 PM Taylor Stacy L SVP and General Counsel Aug 22 '24 Sale 4.50 26,922 121,079 139,365 Aug 23 04:27 PM STACY L TAYLOR Officer Aug 22 '24 Proposed Sale 4.50 26,922 121,079 Aug 22 04:18 PM
Index -
P/E -
EPS (ttm) -3.45
Insider Own 0.36%
Shs Outstand 90.20M
Perf Week -19.55%
Market Cap 582.69M
Forward P/E 7.45
EPS next Y 0.87
Insider Trans -5.42%
Shs Float 89.88M
Perf Month -39.57%
Income -308.90M
PEG -
EPS next Q -0.02
Inst Own 104.25%
Short Float 8.75%
Perf Quarter -65.36%
Sales 2.70B
P/S 0.22
EPS this Y 49.00%
Inst Trans -14.06%
Short Ratio 4.02
Perf Half Y -66.27%
Book/sh 15.19
P/B 0.43
EPS next Y 76.35%
ROA -6.84%
Short Interest 7.87M
Perf Year -83.27%
Cash/sh 1.31
P/C 4.92
EPS next 5Y 60.78%
ROE -17.51%
52W Range 6.73 - 40.57
Perf YTD -65.36%
Dividend Est. -
P/FCF 2.46
EPS past 5Y 3.94%
ROI -12.49%
52W High -84.08%
Beta 2.00
Dividend TTM -
Quick Ratio 1.00
Sales past 5Y 1.61%
Gross Margin 16.65%
52W Low -4.01%
ATR (14) 0.68
Dividend Ex-Date -
Current Ratio 1.00
EPS Y/Y TTM -9015.30%
Oper. Margin -4.15%
RSI (14) 21.11
Volatility 8.59% 6.45%
Employees 15500
Debt/Eq 0.88
Sales Y/Y TTM -13.27%
Profit Margin -11.46%
Recom 3.00
Target Price 11.40
Option/Short Yes / Yes
LT Debt/Eq 0.81
EPS Q/Q -78.19%
Payout -
Rel Volume 1.50
Prev Close 6.79
Sales Surprise -0.89%
EPS Surprise -50.66%
Sales Q/Q -10.11%
Earnings Mar 03 BMO
Avg Volume 1.96M
Price 6.46
SMA20 -25.83%
SMA50 -47.63%
SMA200 -66.10%
Trades
Volume 2,933,114
Change -4.86%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-11-24 Downgrade
Citigroup
Buy → Neutral
$30 → $23
Dec-06-24 Downgrade
Robert W. Baird
Outperform → Neutral
$28 → $25
Sep-25-24 Downgrade
Jefferies
Buy → Hold
$25 → $21
Aug-08-24 Downgrade
Evercore ISI
Outperform → In-line
$31 → $27
Jul-24-24 Resumed
Barclays
Equal Weight
$30
Jun-06-24 Initiated
Goldman
Neutral
$28
May-29-24 Initiated
TD Cowen
Hold
$27
May-28-24 Initiated
Mizuho
Neutral
$27
Mar-22-24 Initiated
Robert W. Baird
Neutral
$43
Mar-06-24 Initiated
Deutsche Bank
Hold
$36
Jan-05-24 Initiated
William Blair
Mkt Perform
Jan-04-24 Initiated
Jefferies
Buy
$44
Dec-11-23 Upgrade
Citigroup
Neutral → Buy
$34 → $40
Dec-01-23 Upgrade
Evercore ISI
In-line → Outperform
$32 → $36
Nov-14-23 Upgrade
Barclays
Equal Weight → Overweight
$29 → $38
Oct-19-23 Initiated
Citigroup
Neutral
$32
Sep-14-23 Initiated
Evercore ISI
In-line
$31
Aug-16-23 Initiated
Barclays
Equal Weight
$29
Aug-07-23 Initiated
BofA Securities
Underperform
$27
Show Previous Ratings
Mar-31-25 08:05AM
Mar-25-25 09:00PM
Mar-20-25 08:07PM
(Morningstar Research) -5.29%
Mar-18-25 05:04AM
Mar-04-25 02:02AM
01:04AM
Loading…
01:04AM
Mar-03-25 06:45AM
Feb-21-25 03:33PM
Feb-20-25 07:00AM
Feb-06-25 07:17PM
Jan-30-25 07:00AM
Dec-07-24 05:15AM
Dec-05-24 04:05PM
Nov-26-24 04:15PM
04:15PM
06:45AM
Loading…
Nov-12-24 06:45AM
Nov-11-24 12:31PM
Nov-09-24 02:04AM
Nov-08-24 10:15AM
06:30AM
Oct-17-24 07:00AM
Oct-14-24 07:00AM
Aug-13-24 12:58PM
(Morningstar Research) +10.88%
Aug-12-24 07:04PM
(Morningstar Research) -20.35%
07:00AM
Jul-17-24 07:00AM
Jul-11-24 08:42AM
08:00AM
Jun-27-24 07:00AM
Jun-19-24 05:02PM
07:00AM
Loading…
Jun-04-24 07:00AM
Jun-03-24 07:00AM
May-30-24 07:01PM
07:00AM
May-21-24 09:48AM
May-17-24 10:15PM
May-16-24 04:05PM
May-15-24 03:56PM
May-14-24 06:43PM
03:01AM
May-13-24 06:50PM
(Morningstar Research) -14.90%
10:52AM
06:30AM
May-06-24 08:22AM
Apr-30-24 01:58PM
Apr-11-24 07:00AM
Mar-12-24 11:24AM
Mar-11-24 06:30AM
06:30AM
Feb-20-24 04:05PM
07:00AM
Jan-29-24 07:00AM
Jan-09-24 04:22PM
Jan-08-24 07:00AM
Jan-05-24 04:53AM
Jan-04-24 08:00AM
Jan-02-24 07:00AM
Dec-13-23 07:00AM
Nov-20-23 07:00AM
Nov-14-23 08:33PM
(Morningstar Research) +5.05%
Nov-13-23 11:07AM
06:30AM
Nov-02-23 07:00AM
Oct-18-23 05:40AM
Oct-17-23 01:35PM
09:05AM
Oct-16-23 08:30PM
(The Wall Street Journal)
Oct-13-23 07:00AM
Oct-11-23 07:00AM
Oct-10-23 07:00AM
Oct-06-23 04:52AM
Sep-15-23 08:45PM
Sep-06-23 11:00AM
11:00AM
Aug-16-23 10:00AM
Aug-15-23 07:03AM
07:03AM
Aug-14-23 07:00AM
Aug-07-23 09:57AM
09:57AM
Jul-20-23 07:00AM
Jul-18-23 07:40AM
Jul-07-23 12:00PM
(The Wall Street Journal) -5.21%
Jun-28-23 06:08PM
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hanson James S. General Counsel Mar 13 '25 Option Exercise 0.00 2,998 0 10,473 Mar 17 04:37 PM Hanson James S. General Counsel Mar 14 '25 Sale 9.70 1,007 9,768 9,466 Mar 17 04:37 PM Morais Mark A. Chief Operating Officer Mar 13 '25 Option Exercise 0.00 4,283 0 39,879 Mar 17 04:35 PM Morais Mark A. Chief Operating Officer Mar 14 '25 Sale 9.70 1,207 11,708 38,672 Mar 17 04:35 PM Mcconnell Jill G. Chief Financial Officer Mar 13 '25 Option Exercise 0.00 4,283 0 41,677 Mar 17 04:33 PM Mcconnell Jill G. Chief Financial Officer Mar 14 '25 Sale 9.70 1,210 11,737 40,467 Mar 17 04:33 PM Morais Mark A. Chief Operating Officer Mar 12 '25 Option Exercise 0.00 725 0 35,799 Mar 14 04:32 PM Morais Mark A. Chief Operating Officer Mar 13 '25 Sale 9.93 203 2,016 35,596 Mar 14 04:32 PM Mcconnell Jill G. Chief Financial Officer Mar 12 '25 Option Exercise 0.00 935 0 37,655 Mar 14 04:31 PM Mcconnell Jill G. Chief Financial Officer Mar 13 '25 Sale 9.93 261 2,592 37,394 Mar 14 04:31 PM Hanson James S. Officer Mar 14 '25 Proposed Sale 9.70 1,007 9,766 Mar 14 03:40 PM Morais Mark A. Officer Mar 14 '25 Proposed Sale 9.70 1,207 11,705 Mar 14 03:40 PM Mcconnell Jill G. Officer Mar 14 '25 Proposed Sale 9.70 1,210 11,735 Mar 14 03:40 PM Morais Mark A. Chief Operating Officer Mar 11 '25 Option Exercise 0.00 1,573 0 35,573 Mar 13 04:54 PM Morais Mark A. Chief Operating Officer Mar 12 '25 Sale 9.98 499 4,980 35,074 Mar 13 04:54 PM Mcconnell Jill G. Chief Financial Officer Mar 11 '25 Option Exercise 0.00 2,028 0 37,363 Mar 13 04:53 PM Mcconnell Jill G. Chief Financial Officer Mar 12 '25 Sale 9.98 643 6,417 36,720 Mar 13 04:53 PM Morais Mark A. Officer Mar 13 '25 Proposed Sale 9.93 203 2,015 Mar 13 03:18 PM Mcconnell Jill G. Officer Mar 13 '25 Proposed Sale 9.93 261 2,591 Mar 13 03:15 PM Morais Mark A. Officer Mar 12 '25 Proposed Sale 9.98 499 4,980 Mar 12 03:15 PM Mcconnell Jill G. Officer Mar 12 '25 Proposed Sale 9.98 643 6,417 Mar 12 03:09 PM ECKERT R ANDREW Director Feb 21 '25 Option Exercise 0.00 7,282 0 13,636 Feb 25 05:12 PM Morais Mark A. Chief Operating Officer Feb 11 '25 Option Exercise 0.00 1,210 0 34,424 Feb 13 05:30 PM Morais Mark A. Chief Operating Officer Feb 12 '25 Sale 14.67 424 6,220 34,000 Feb 13 05:30 PM Mcconnell Jill G. Chief Financial Officer Feb 11 '25 Option Exercise 0.00 1,544 0 35,875 Feb 13 05:28 PM Mcconnell Jill G. Chief Financial Officer Feb 12 '25 Sale 14.67 540 7,922 35,335 Feb 13 05:28 PM Mcconnell Jill G. Officer Feb 12 '25 Proposed Sale 14.67 540 7,923 Feb 12 03:18 PM Morais Mark A. Officer Feb 12 '25 Proposed Sale 14.67 424 6,221 Feb 12 03:15 PM Mcconnell Jill G. Chief Financial Officer Feb 07 '25 Option Exercise 0.00 1,687 0 34,909 Feb 11 04:44 PM Mcconnell Jill G. Chief Financial Officer Feb 10 '25 Sale 14.80 578 8,554 34,331 Feb 11 04:44 PM Morais Mark A. Chief Operating Officer Feb 07 '25 Option Exercise 0.00 2,256 0 33,987 Feb 11 04:42 PM Morais Mark A. Chief Operating Officer Feb 10 '25 Sale 14.80 773 11,440 33,214 Feb 11 04:42 PM Morais Mark A. Officer Feb 10 '25 Proposed Sale 14.80 773 11,440 Feb 10 04:22 PM Mcconnell Jill G. Officer Feb 10 '25 Proposed Sale 14.80 578 8,554 Feb 10 04:07 PM Pike Thomas Chief Executive Officer Jan 10 '25 Option Exercise 0.00 40,220 0 171,136 Jan 14 06:08 PM Pike Thomas Chief Executive Officer Jan 13 '25 Sale 18.04 11,268 203,275 159,868 Jan 14 06:08 PM Pike Thomas Officer Jan 13 '25 Proposed Sale 18.04 11,268 203,288 Jan 13 03:12 PM Morais Mark A. Chief Operating Officer Dec 15 '24 Option Exercise 0.00 406 0 31,910 Dec 17 05:18 PM Morais Mark A. Chief Operating Officer Aug 19 '24 Option Exercise 0.00 11,312 0 36,464 Aug 20 05:37 PM Mcconnell Jill G. Chief Financial Officer Aug 19 '24 Option Exercise 0.00 11,312 0 38,194 Aug 20 05:36 PM Pike Thomas Chief Executive Officer Aug 19 '24 Option Exercise 0.00 125,691 0 183,518 Aug 20 05:34 PM Smith David Ross Director Jul 18 '24 Option Exercise 0.00 6,354 0 6,354 Jul 19 05:24 PM NEUPERT PETER M Director Jul 18 '24 Option Exercise 0.00 6,354 0 28,350 Jul 19 05:23 PM Pesicka Edward A Director Jul 18 '24 Option Exercise 0.00 6,354 0 6,354 Jul 19 05:23 PM ECKERT R ANDREW Director Jul 18 '24 Option Exercise 0.00 6,354 0 6,354 Jul 19 05:22 PM Ray Amrit Director Jul 18 '24 Option Exercise 0.00 6,354 0 6,354 Jul 19 05:21 PM Hanson James S. General Counsel Jun 12 '24 Buy 25.30 2,000 50,600 7,475 Jun 12 06:28 PM Hanson James S. General Counsel Jun 03 '24 Option Exercise 0.00 7,706 0 7,706 Jun 03 07:08 PM Warren Amanda M. Chief Accounting Officer Jun 03 '24 Option Exercise 0.00 3,842 0 6,411 Jun 03 07:05 PM Mcconnell Jill G. Chief Financial Officer Jun 03 '24 Option Exercise 0.00 11,000 0 31,717 Jun 03 07:03 PM Morais Mark A. Chief Operating Officer Jun 03 '24 Option Exercise 0.00 11,000 0 29,406 Jun 03 07:01 PM Pike Thomas Chief Executive Officer May 29 '24 Buy 24.81 10,000 248,066 57,827 May 30 04:34 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite